Alpha Tau Medical announced positive results from pooled Phase I/II trials of its Alpha DaRT therapy for pancreatic cancer, showing improved median overall survival (mOS) across various patient groups compared to historical chemotherapy data. The one-time, minimally invasive treatment demonstrated mOS up to 17 months in some groups, with a favorable safety profile and no chronic toxicity. These findings support ongoing trials, including the U.S. IMPACT study combining Alpha DaRT with chemotherapy, aiming to enhance local tumor control without increasing systemic side effects. This advancement offers hope for better treatment options in a cancer type with historically poor outcomes.
NVIDIA announced that leading Japanese companies in robotics and manufacturing are adopting its Cosmos, Isaac, Metropolis, and Jetson platforms to accelerate AI-powered intelligent machines across industries. The new Cosmos 3 Edge model enables real-...
Oil prices are rising sharply due to renewed US naval blockades on Iranian shipping and increased tensions in the Strait of Hormuz, a critical oil transit route. Brent crude is holding above $85 and WTI above $80, with forecasts suggesting WTI could ...
The US government announced it will impose a new 25% tariff on Brazilian ethanol starting next Wednesday, accusing Brazil of unfair trade practices. This tariff excludes major Brazilian exports like oil, beef, coffee, and aircraft parts. The move fol...
Alibaba and Baidu shares rose after Apple received approval from China's Cyberspace Administration to include Apple Intelligence, integrating Alibaba's Qwen AI model and Baidu's AI features into Apple devices in China. This partnership allows users t...
Ondo Finance has introduced the first tokenized stock representations backed by DTCC tokenized entitlements, joining major financial firms in a significant tokenization initiative. This move highlights Ondo's unique position in building infrastructur...
